论文部分内容阅读
本文观察224例急性心肌梗塞(AMI)入院当日血清镁,平均值0.82mmol/L,其中有和无并发重症室性心律失常者的血清镁((?)±S)分别为0.76±0.08与0.82±0.08mmol/L,P<0.01。用随机双盲法将入院病人224例分为两组,136例为镁盐治疗组,另88例为对照组。治疗组与对照组相比:重症室性心律失常发生率为17%与41.5%(P<0.01);重症性心律失常致死者为0.7%与4.5(P<0.05);死于泵衰竭者为1.4%与5.6%(P<0.05);总病死率为2.1%与10.1%(P<0.05)。镁盐治疗组均无不良反应。表明 AMI 早期静脉滴注镁盐确有安全、有效、简单、易行,可作为 AMI 常规治疗的一种措施。
In this paper, 224 patients with acute myocardial infarction (AMI) on the day of admission serum magnesium, the average of 0.82mmol / L, with and without recurrent ventricular arrhythmia serum magnesium (± s) were 0.76 ± 0.08 and 0.82 ± 0.08 mmol / L, P <0.01. 224 patients admitted to hospital were divided into two groups by randomized double-blind method, 136 patients were treated with magnesium salt and the other 88 patients as control group. The incidence of severe ventricular arrhythmia was 17% and 41.5% in the treatment group compared with the control group (P <0.01), 0.7% and 4.5 (P <0.05) in the patients with severe arrhythmia, and those who died of pump failure were 1.4% and 5.6% respectively (P <0.05). The total case fatality rates were 2.1% and 10.1% (P <0.05). There was no adverse reaction in the magnesium salt treatment group. It shows that the early intravenous infusion of AMI magnesium salt is safe, effective, simple and easy, and can be used as a routine AMI treatment measures.